Filtered By:
Management: Funding

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 373 results found since Jan 2013.

NIDCR's Winter 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Winter 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News   NIDCR News NIDCR Welcomes New Director Rena D’Souza Rena N. D’Souza, DDS, MS, PhD, was sworn in as the director of NIDCR by NIH Director Francis S. Collins, MD, PhD, on October 13. Prior to joining NIH, Dr. D’Souza was the assistant vice president for academic affairs and education for health sciences at the Unive...
Source: NIDCR Science News - December 4, 2020 Category: Dentistry Source Type: news

Covid-19 affects people differently. NC firm looks to figure out why.
A well known phenomenon of the Covid-19 era is that the deadly virus presents a wide disparity of symptoms between patients – now a Triangle firm has the federal funding to try to find out why. Last week, Morrisville-based Metabolon was selected by the National Institute of Allergy and Infectious Diseases (NIAID) to be a lead in its "Immunophenotyping Assessment in a Covid-19 Cohort," or IMPACC, study. The study i s an initiative to dive into the human immune system response to the virus behind…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 29, 2020 Category: Pharmaceuticals Authors: Seth Thomas Gulledge Source Type: news

The Covid Pandemic: Broadening the Discourse
Thailand’s COVID-19 response an example of resilience and solidarity: a UN Resident Coordinator’s BlogBy Asoka BandarageCOLOMBO, Sri Lanka, Nov 10 2020 (IPS) SARS-CoV-2, the corona virus that causes COVID-19, has been spreading exponentially across the world over the last ten or so months. As of November 6th, according to the Center for Systems Science at Johns Hopkins University, there have been 49,195,581 cases of COVID-19, including 1,241,031 deaths. More than a third of the global population has been placed on lockdown. The global economy is experiencing the deepest global recession since World War 2 and massive n...
Source: IPS Inter Press Service - Health - November 10, 2020 Category: International Medicine & Public Health Authors: Asoka Bandarage Tags: Featured Global Headlines Health Human Rights Humanitarian Emergencies Peace TerraViva United Nations Source Type: news

Biden ’s Real COVID-19 Challenge Is Restoring a Nation’s Trust in Science
“If the public-health professionals, if Dr. [Anthony] Fauci, if doctors tell us we should take it, I would be first in line. If Donald Trump tells us we should take it, then I’m not taking it.” That was Vice President-elect Kamala Harris’ response when asked by the moderator of an Oct. 7 debate whether she would get vaccinated against COVID-19. It perfectly captured the politicization of the U.S. response to COVID-19 under the outgoing Trump Administration—and how dangerous that red and blue tinting of the pandemic response has been for the American public. Behaviors like wearing masks and soc...
Source: TIME: Health - November 7, 2020 Category: Consumer Health News Authors: Jamie Ducharme and Alice Park Tags: Uncategorized COVID-19 Source Type: news

News & Notes
Obtaining funding for research and other projects in allergy/immunology can be a challenge. The AAAAI is committed to helping members of the A/I community obtain access to funds that will allow them to conduct important research and complete projects relevant to the A/I field. The AAAAI Foundation does this by raising money for the annual Faculty Development Awards, but there is an additional grant opportunity still accepting applications that you may not be aware of:
Source: Journal of Allergy and Clinical Immunology - November 1, 2020 Category: Allergy & Immunology Source Type: research

UCLA draws record $1.4 billion in research funding
UCLA attracted record support for its wide-ranging research in the 2019 –20 fiscal year, receiving $1.427 billion in research funding.2020 is the third consecutive year that the university has topped its previous best. Research support has grown by 38% since 2015. UCLA now ranks sixth among all universities in total research expenditures.“This is a tribute to the great work being done across disciplines at UCLA,” said Roger Wakimoto, vice chancellor for research. “These funds help bring about major breakthroughs in medical science, advance knowledge in numerous other disciplines, strengthen our teaching, and suppor...
Source: UCLA Newsroom: Health Sciences - October 12, 2020 Category: Universities & Medical Training Source Type: news

NIH trial testing hyperimmune intravenous immunoglobulin and remdesivir to treat COVID-19
(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for COVID-19 consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2 has begun. The study is taking place in hospitalized adults with COVID-19 in the United States, Mexico and 16 other countries on five continents. NIAID is sponsoring and funding the Phase 3 trial, called Inpatient Treatment with Anti-Coronavirus Immunoglobulin, or ITAC.
Source: EurekAlert! - Infectious and Emerging Diseases - October 8, 2020 Category: Infectious Diseases Source Type: news

COVID-19 research funding targets role of genes, environment
<div class="rxbodyfield">NIEHS and the National Institute of Allergy and Infectious Diseases seek to understand why some people are more vulnerable to the disease.</div> (read more)
Source: Environmental Factor - NIEHS Newsletter - October 3, 2020 Category: Environmental Health Source Type: news

Johnson & Johnson ’ s Coronavirus Vaccine Enters Phase 3 Trial With Beth Israel
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p1").init({"mcp":"cbs","width":"100%","height":"100%","video":"4730668","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p1","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","jobId":"sc_va","marketingCloudId":"823BA0335567497F7F000101@AdobeOrg","trackingServer":"cbsdigitalmedia.hb.omtrdc.net","customTrackingServer":"cbsdigitalmedia.d1.sc.omtrdc.net","chapterTracking":false,"version":"1.5"},"comscore":{"clientId"...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 23, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Covid-19 Boston, MA Health Healthcare Status Beth Israel Deacones Medical Center Coronavirus Johnson & Johnson Source Type: news

The Great Vaccine Race: Inside the Unprecedented Scramble to Immunize the World Against COVID-19
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins. Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news

Cutaneous Radiation Injuries: Models, Assessment and Treatments.
This report provides an overview of information that was presented and the subsequent guided discussions. PMID: 32857831 [PubMed - as supplied by publisher]
Source: Radiation Research - August 27, 2020 Category: Physics Authors: DiCarlo AL, Bandremer AC, Hollingsworth BA, Kasim S, Laniyonu A, Todd NF, Wang SJ, Wertheimer ER, Rios CI Tags: Radiat Res Source Type: research

Single-use N95 respirators can be decontaminated and used again, study finds
N95 respirators,which are widely worn by health care workers treating patients with COVID-19and are designed to be used only once, can be decontaminated effectively and used up to three times, according to research by UCLA scientists and colleagues.An early-release version of their study has beenpublished online, with the full study to appear in September in the journal Emerging Infectious Diseases.N95 respirators reduce exposure to airborne infectious agents,including SARS-CoV-2, the virus that causes COVID-19,and are one of the key pieces of personal protective equipment used by clinical workers in preventing the spread ...
Source: UCLA Newsroom: Health Sciences - August 27, 2020 Category: Universities & Medical Training Source Type: news

Moderna ’s COVID-19 Vaccine Enters Final Testing Phase, As Researchers Dose the Study’s First Volunteer
Moderna Therapeutics and the National Institute of Allergy and Infectious Diseases (NIAID) announced today that researchers had injected the first volunteer in the first U.S. coronavirus vaccine to reach the final, phase 3 stage of testing. That person received the shot at 6:45 am eastern time in Savannah, Geo., Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) told reporters during a briefing. Because the trial will randomly assign participants to receive either the vaccine or a placebo, and neither the researchers nor the volunteers will kn...
Source: TIME: Health - July 27, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Nuclear fallout drug gets funding to test Covid-19 patients
A drug designed to protect soldiers and citizens from nuclear bombs is now being used to study patients recovering from Covid-19. Edina-based Humanetics Corp. announced Thursday it received funding from the National Institute of Allergy and Infectious Diseases (NIAID) to conduct a study of its drug, BIO 300, in Covid-19 patients. The study will focus on patients who were treated for severe cases of Covid-19. Many of these patients are out of the hospital, but still face the possibility their…
Source: bizjournals.com Health Care:Biotechnology headlines - July 23, 2020 Category: Biotechnology Authors: Carter Jones Source Type: news